345 related articles for article (PubMed ID: 15994976)
1. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.
Debes JD; Comuzzi B; Schmidt LJ; Dehm SM; Culig Z; Tindall DJ
Cancer Res; 2005 Jul; 65(13):5965-73. PubMed ID: 15994976
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus.
Jia L; Coetzee GA
Cancer Res; 2005 Sep; 65(17):8003-8. PubMed ID: 16140973
[TBL] [Abstract][Full Text] [Related]
3. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar MD; Gleave ME
Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
[TBL] [Abstract][Full Text] [Related]
4. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
Hobisch A; Eder IE; Putz T; Horninger W; Bartsch G; Klocker H; Culig Z
Cancer Res; 1998 Oct; 58(20):4640-5. PubMed ID: 9788616
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation increases p300 expression in prostate cancer cells.
Heemers HV; Sebo TJ; Debes JD; Regan KM; Raclaw KA; Murphy LM; Hobisch A; Culig Z; Tindall DJ
Cancer Res; 2007 Apr; 67(7):3422-30. PubMed ID: 17409453
[TBL] [Abstract][Full Text] [Related]
7. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
Paliouras M; Diamandis EP
Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
[TBL] [Abstract][Full Text] [Related]
8. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6.
Debes JD; Schmidt LJ; Huang H; Tindall DJ
Cancer Res; 2002 Oct; 62(20):5632-6. PubMed ID: 12384515
[TBL] [Abstract][Full Text] [Related]
9. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression.
Agoulnik IU; Vaid A; Bingman WE; Erdeme H; Frolov A; Smith CL; Ayala G; Ittmann MM; Weigel NL
Cancer Res; 2005 Sep; 65(17):7959-67. PubMed ID: 16140968
[TBL] [Abstract][Full Text] [Related]
10. Rap2 regulates androgen sensitivity in human prostate cancer cells.
Bigler D; Gioeli D; Conaway MR; Weber MJ; Theodorescu D
Prostate; 2007 Oct; 67(14):1590-9. PubMed ID: 17918750
[TBL] [Abstract][Full Text] [Related]
11. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
[TBL] [Abstract][Full Text] [Related]
12. The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus.
Kim J; Jia L; Stallcup MR; Coetzee GA
J Mol Endocrinol; 2005 Feb; 34(1):107-18. PubMed ID: 15691881
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line.
Tsui KH; Feng TH; Chung LC; Chao CH; Chang PL; Juang HH
Anticancer Res; 2008; 28(4A):1969-76. PubMed ID: 18649734
[TBL] [Abstract][Full Text] [Related]
14. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells.
Tsui KH; Feng TH; Lin CM; Chang PL; Juang HH
J Androl; 2008; 29(6):661-8. PubMed ID: 18676361
[TBL] [Abstract][Full Text] [Related]
15. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.
Clark DE; Errington TM; Smith JA; Frierson HF; Weber MJ; Lannigan DA
Cancer Res; 2005 Apr; 65(8):3108-16. PubMed ID: 15833840
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-4 in patients with prostate cancer.
Takeshi U; Sadar MD; Suzuki H; Akakura K; Sakamoto S; Shimbo M; Suyama T; Imamoto T; Komiya A; Yukio N; Ichikawa T
Anticancer Res; 2005; 25(6C):4595-8. PubMed ID: 16334148
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.
Jia L; Kim J; Shen H; Clark PE; Tilley WD; Coetzee GA
Mol Cancer Res; 2003 Mar; 1(5):385-92. PubMed ID: 12651911
[TBL] [Abstract][Full Text] [Related]
19. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
Suzuki S; Tadakuma T; Asano T; Hayakawa M
Cancer Res; 2001 Feb; 61(4):1276-9. PubMed ID: 11245419
[TBL] [Abstract][Full Text] [Related]
20. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
